Dr. Shore on VISION trial and future of PSMA-targeted agents in prostate cancer

Neal D. Shore, MD, discusses the phase 3 VISION trial, in which adding the targeted radioligand therapy 177Lu-PSMA-617 to standard of care (SOC) led to a nearly 40% reduction in the risk of death versus SOC alone in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer. Shore, who is medical director of the Carolina Urologic Research Center, also provides insight on the next steps with PSMA-targeted agents in prostate cancer.